: Sputnik V shows efficacy in fighting COVID-19 internationally peer-reviewed data #IndiaNEWS #Press Release In an interim analysis of a Phase III clinical trial, Sputnik V showedstrong efficacy, immunogenicity

Sputnik V shows efficacy in fighting COVID-19 internationally peer-reviewed data #IndiaNEWS #Press Release
In an interim analysis of a Phase III clinical trial, Sputnik V showedstrong efficacy, immunogenicity and safety results.

Efficacy of Sputnik V against COVID-19 was reported at 91. 6%.

The analysis included data on 19,866 volunteers, who received both the first and second doses of the Sputnik V vaccine or placebo at the final control point of 78 confirmed COVID-19 cases.

Efficacy in the elderly group of 2,144 volunteers over 60 years old was 91. 8% and did not differ statistically from the 18-60 group.

Sputnik V provides full protection against severe cases of COVID-19.

Among the cases analyzed, over 98% of volunteers developed humoral immune response and 100% cellular immune response.

The level of virus-neutralizing antibodies of volunteers vaccinated with Sputnik V is 1. 3-1. 5 times higher than the level of antibodies of patients who recovered from COVID-19.

Excellent safety profile. Most adverse events (94%) were mild and included flu-like syndromes, injection site reactions, headache, and asthenia.

No serious adverse events associated with vaccination, as confirmed by Independent Data Monitoring Committee.

No strong allergies, no anaphylactic shock.

Sputnik V is one of the three vaccines in the world with an efficacy of over 90%. Furthermore, Sputnik V stands out among these vaccines thanks to a number of key advantages.

Based on a platform of human adenoviral vectors proven to be safe over decades of use. Easy distribution worldwide: storage temperature of between two and eight degrees Celsius. One of the most affordable vaccines in the world with a price of less than 10 per shot.

Sputnik V is already registered in 16 countries: Russia, Belarus, Serbia, Argentina, Bolivia, Algeria, Palestine, Venezuela, Paraguay, Turkmenistan, Hungary, UAE, Iran, Republic of Guinea, Tunisia, and Armenia.

In the first week of February, vaccination with Sputnik V will start in the following 12 countries: Bolivia, Kazakhstan, Turkmenistan, Palestine, UAE, Paraguay, Hungary, Armenia, Algeria, Bosnian Serb Republic, Venezuela, and Iran.

In 10 countries out of 12, Sputnik V will be the first coronavirus vaccine approved for civil circulation.

The Gamaleya National Research Center of Epidemiology and Microbiology of the Ministry of Health of the Russian Federation and the Russian Direct Investment Fund (RDIF, Russias sovereign wealth fund) announce that the Lancet, one of the worlds oldest and most respected medical journals, has published interim results of a Phase III clinical trial of Sputnik V, confirming the vaccines high efficacy and safety. Sputnik V, which is based on a well-studied human adenoviral vectors platform, is the worlds first registered vaccine against coronavirus.